A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

← catalyst calendar

NCT07395687 · readout in 148 d

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

333estimated

Sites

Countries

Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-02-02

actual

When the study began enrolling

Primary completion

2027-01-14

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-02-18

estimated

The whole study's end, after follow-up

First posted

2026-02-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-21

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Overweight
Obesity

Interventions

Drug: UBT251
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part A - Number of treatment emergent adverse events (TEAEs)

measured From baseline (week 0) to end of study (week 33)

Part B - Relative change in body weight

measured From baseline (week 0) to end of treatment (week 28)

Part C- AUC; the area under the UBT251 plasma concentration time curve

measured From pre-dose on Day 1 until completion of the end of study visit (Day 43)

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed